Skip to main content
Top
Published in: Respiratory Research 1/2024

Open Access 01-12-2024 | Spirometry | Research

Feasibility and acceptability of remotely monitoring spirometry and pulse oximetry as part of interstitial lung disease clinical care: a single arm observational study

Authors: Sarah Barth, Colin Edwards, Gauri Saini, Yussef Haider, Nicholas Paul Williams, Will Storrar, Gisli Jenkins, Iain Stewart, Melissa Wickremasinghe

Published in: Respiratory Research | Issue 1/2024

Login to get access

Abstract

Background

Remote monitoring of patient-recorded spirometry and pulse oximetry offers an alternative approach to traditional hospital-based monitoring of interstitial lung disease (ILD). Remote spirometry has been observed to reasonably reflect clinic spirometry in participants with ILD but remote monitoring has not been widely incorporated into clinical practice. We assessed the feasibility of remotely monitoring patients within a clinical ILD service.

Methods

Prospective, single-arm, open-label observational multi-centre study (NCT04850521). Inclusion criteria included ILD diagnosis, age ≥ 18 years, FVC ≥ 50% predicted. 60 participants were asked to record a single spirometry and oximetry measurement at least once daily, monitored weekly by their local clinical team. Feasibility was defined as ≥ 68% of participants with ≥ 70% adherence to study measurements and recording measurements ≥ 3 times/week throughout.

Results

A total of 60 participants were included in the analysis. 42/60 (70%) were male; mean age 67.8 years (± 11.2); 34/60 (56.7%) had idiopathic pulmonary fibrosis (IPF), Median ILD-GAP score was 3 (IQR 1–4.75). Spirometry adherence was achieved for ≥ 70% of study days in 46/60 participants (77%) and pulse oximetry adherence in 50/60 participants (83%). Recording ≥ 3 times/week every week was provided for spirometry in 41/60 participants (68%) and pulse oximetry in 43/60 participants (72%). Mean difference between recent clinic and baseline home spirometry was 0.31 L (± 0.72). 85.7% (IQR 63.9–92.6%) home spirometry attempts/patient were acceptable or usable according to ERS/ATS spirometry criteria. Positive correlation was observed between ILD-GAP score and adherence to spirometry and oximetry (rho 0.24 and 0.38 respectively). Adherence of weekly monitoring by clinical teams was 80.95% (IQR 64.19–95.79). All participants who responded to an experience questionnaire (n = 33) found remote measurements easy to perform and 75% wished to continue monitoring their spirometry at the conclusion of the study.

Conclusion

Feasibility of remote monitoring within an ILD clinical service was demonstrated over 3 months for both daily home spirometry and pulse oximetry of patients. Remote monitoring may be more acceptable to participants who are older or have more advanced disease.

Trial Registration

clinicaltrials.gov NCT04850521 registered 20th April 2021
Appendix
Available only for authorised users
Literature
2.
go back to reference Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice Guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.CrossRefPubMed Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice Guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.CrossRefPubMed
3.
go back to reference Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–47.CrossRefPubMedPubMedCentral Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–47.CrossRefPubMedPubMedCentral
4.
go back to reference Wells AU, Denton CP. Interstitial lung disease in connective tissue disease—mechanisms and management. Nat Rev Rheumatol. 2014;10(12):728–39.CrossRefPubMed Wells AU, Denton CP. Interstitial lung disease in connective tissue disease—mechanisms and management. Nat Rev Rheumatol. 2014;10(12):728–39.CrossRefPubMed
5.
go back to reference Jegal Y, Kim DS, Shim TS, Lim C-M, Lee SD, Koh Y, et al. Physiology is a stronger predictor of Survival than Pathology in Fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171(6):639–44.CrossRefPubMed Jegal Y, Kim DS, Shim TS, Lim C-M, Lee SD, Koh Y, et al. Physiology is a stronger predictor of Survival than Pathology in Fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171(6):639–44.CrossRefPubMed
6.
go back to reference King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of Pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.CrossRefPubMed King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of Pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.CrossRefPubMed
7.
go back to reference Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22):2071–82.CrossRefPubMed Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22):2071–82.CrossRefPubMed
8.
go back to reference Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in Progressive Fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–27.CrossRefPubMed Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in Progressive Fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–27.CrossRefPubMed
9.
go back to reference Russell A-M, Adamali H, Molyneaux PL, Lukey PT, Marshall RP, Renzoni EA, et al. Daily Home Spirometry: An Effective Tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194(8):989–97.CrossRefPubMedPubMedCentral Russell A-M, Adamali H, Molyneaux PL, Lukey PT, Marshall RP, Renzoni EA, et al. Daily Home Spirometry: An Effective Tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194(8):989–97.CrossRefPubMedPubMedCentral
10.
go back to reference Johannson KA. Remote monitoring in idiopathic pulmonary fibrosis: home is where the bluetooth-enabled spirometer is. Am J Respir Crit Care Med. 2020;202(3):316–7.CrossRefPubMedPubMedCentral Johannson KA. Remote monitoring in idiopathic pulmonary fibrosis: home is where the bluetooth-enabled spirometer is. Am J Respir Crit Care Med. 2020;202(3):316–7.CrossRefPubMedPubMedCentral
11.
go back to reference Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Chavannes NH, et al. Home Monitoring in patients with idiopathic pulmonary fibrosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2020;202(3):393–401.CrossRefPubMed Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Chavannes NH, et al. Home Monitoring in patients with idiopathic pulmonary fibrosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2020;202(3):393–401.CrossRefPubMed
12.
go back to reference Smith AC, Thomas E, Snoswell CL, Haydon H, Mehrotra A, Clemensen J, et al. Telehealth for global emergencies: implications for coronavirus disease 2019 (COVID-19). J Telemed Telecare. 2020;26(5):309–13.CrossRefPubMed Smith AC, Thomas E, Snoswell CL, Haydon H, Mehrotra A, Clemensen J, et al. Telehealth for global emergencies: implications for coronavirus disease 2019 (COVID-19). J Telemed Telecare. 2020;26(5):309–13.CrossRefPubMed
13.
go back to reference Mecklai K, Smith N, Stern AD, Kramer DB. Remote patient monitoring — overdue or overused? N Engl J Med. 2021;384(15):1384–6.CrossRefPubMed Mecklai K, Smith N, Stern AD, Kramer DB. Remote patient monitoring — overdue or overused? N Engl J Med. 2021;384(15):1384–6.CrossRefPubMed
14.
go back to reference Nakshbandi G, Moor CC, Johannson KA, Maher TM, Kreuter M, Wijsenbeek MS. Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era. ERJ Open Res. 2021;7(3). Nakshbandi G, Moor CC, Johannson KA, Maher TM, Kreuter M, Wijsenbeek MS. Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era. ERJ Open Res. 2021;7(3).
15.
go back to reference Cardeñosa SC, Palomo M, Francesqui J, Alsina X, Hernández C, Albacar N, et al. Home oxygen monitoring in patients with interstitial lung disease. Annals Am Thorac Soc. 2022;19(3):493–7.CrossRef Cardeñosa SC, Palomo M, Francesqui J, Alsina X, Hernández C, Albacar N, et al. Home oxygen monitoring in patients with interstitial lung disease. Annals Am Thorac Soc. 2022;19(3):493–7.CrossRef
16.
go back to reference Joshi E, Mann JM, Goodwin ME, Collins AL, Atkins NE, Khor YH et al. Perceptions of individuals with chronic lung disease on Home Use of Pulse Oximetry. Respir Care. 2022. Joshi E, Mann JM, Goodwin ME, Collins AL, Atkins NE, Khor YH et al. Perceptions of individuals with chronic lung disease on Home Use of Pulse Oximetry. Respir Care. 2022.
17.
go back to reference Clarke J, Flott K, Crespo RF, Ashrafian H, Fontana G, Benger J, et al. Assessing the safety of home oximetry for COVID-19: a multisite retrospective observational study. BMJ open. 2021;11(9):e049235.CrossRefPubMed Clarke J, Flott K, Crespo RF, Ashrafian H, Fontana G, Benger J, et al. Assessing the safety of home oximetry for COVID-19: a multisite retrospective observational study. BMJ open. 2021;11(9):e049235.CrossRefPubMed
18.
go back to reference Connolly SP, Katolo HW, Cronin C, Dingle A, Creed M, Edwards C et al. Ambulatory monitoring of patients with COVID-19: initial experiences and next steps. BMJ Innovations. 2022;8(2). Connolly SP, Katolo HW, Cronin C, Dingle A, Creed M, Edwards C et al. Ambulatory monitoring of patients with COVID-19: initial experiences and next steps. BMJ Innovations. 2022;8(2).
19.
go back to reference Khan F, Howard L, Hearson G, Edwards C, Barber C, Jones S, et al. Clinical utility of Home versus Hospital Spirometry in Fibrotic interstitial lung disease: evaluation after INJUSTIS Interim Analysis. Annals Am Thorac Soc. 2022;19(3):506–9.CrossRef Khan F, Howard L, Hearson G, Edwards C, Barber C, Jones S, et al. Clinical utility of Home versus Hospital Spirometry in Fibrotic interstitial lung disease: evaluation after INJUSTIS Interim Analysis. Annals Am Thorac Soc. 2022;19(3):506–9.CrossRef
20.
go back to reference Johannson KA, Vittinghoff E, Morisset J, Lee JS, Balmes John R, Collard HR. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. Eur Respir J. 2017;50(1):1602406.CrossRefPubMedPubMedCentral Johannson KA, Vittinghoff E, Morisset J, Lee JS, Balmes John R, Collard HR. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. Eur Respir J. 2017;50(1):1602406.CrossRefPubMedPubMedCentral
21.
go back to reference Marcoux V, Wang M, Burgoyne SJ, Fell CD, Ryerson CJ, Sajobi TT, et al. Mobile Health Monitoring in patients with idiopathic pulmonary fibrosis. Annals Am Thorac Soc. 2019;16(10):1327–9.CrossRef Marcoux V, Wang M, Burgoyne SJ, Fell CD, Ryerson CJ, Sajobi TT, et al. Mobile Health Monitoring in patients with idiopathic pulmonary fibrosis. Annals Am Thorac Soc. 2019;16(10):1327–9.CrossRef
22.
go back to reference Moor CC, Wapenaar M, Miedema JR, Geelhoed JJM, Chandoesing PP, Wijsenbeek MS. A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers. Respir Res. 2018;19(1):105.CrossRefPubMedPubMedCentral Moor CC, Wapenaar M, Miedema JR, Geelhoed JJM, Chandoesing PP, Wijsenbeek MS. A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers. Respir Res. 2018;19(1):105.CrossRefPubMedPubMedCentral
23.
go back to reference Althobiani MA, Evans RA, Alqahtani JS, Aldhahir AM, Russell A-M, Hurst JR, et al. Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review. ERJ Open Res. 2021;7(4):00441–2021.CrossRefPubMedPubMedCentral Althobiani MA, Evans RA, Alqahtani JS, Aldhahir AM, Russell A-M, Hurst JR, et al. Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review. ERJ Open Res. 2021;7(4):00441–2021.CrossRefPubMedPubMedCentral
24.
go back to reference Edwards C, Costello E, Cassidy N, Vick B, Russell A-M. Use of the patientMpower app with home-based spirometry to monitor the symptoms and impact of fibrotic lung conditions: longitudinal observational study. JMIR mHealth uHealth. 2020;8(11):e16158.CrossRefPubMedPubMedCentral Edwards C, Costello E, Cassidy N, Vick B, Russell A-M. Use of the patientMpower app with home-based spirometry to monitor the symptoms and impact of fibrotic lung conditions: longitudinal observational study. JMIR mHealth uHealth. 2020;8(11):e16158.CrossRefPubMedPubMedCentral
26.
go back to reference Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the patient activation measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;39(4p1):1005–26.CrossRefPubMedPubMedCentral Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the patient activation measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;39(4p1):1005–26.CrossRefPubMedPubMedCentral
27.
go back to reference Patient. activation measure (PAM) 13™ License Materials2011. Patient. activation measure (PAM) 13™ License Materials2011.
28.
go back to reference Tsai APY, Hur SA, Wong A, Safavi M, Assayag D, Johannson KA, et al. Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax. 2021;76(1):37–43.CrossRefPubMed Tsai APY, Hur SA, Wong A, Safavi M, Assayag D, Johannson KA, et al. Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax. 2021;76(1):37–43.CrossRefPubMed
29.
go back to reference Peters JB, Antons JC, Koolen EH, van Helvoort HA, van Hees HW, van den Borst B, et al. Patient activation is a treatable trait in patients with chronic airway diseases: an observational study. Front Psychol. 2022;13:947402.CrossRefPubMedPubMedCentral Peters JB, Antons JC, Koolen EH, van Helvoort HA, van Hees HW, van den Borst B, et al. Patient activation is a treatable trait in patients with chronic airway diseases: an observational study. Front Psychol. 2022;13:947402.CrossRefPubMedPubMedCentral
30.
go back to reference Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723–8.CrossRefPubMed Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723–8.CrossRefPubMed
31.
go back to reference Das N, Verstraete K, Stanojevic S, Topalovic M, Aerts J-M, Janssens W. Deep-learning algorithm helps to standardise ATS/ERS spirometric acceptability and usability criteria. Eur Respir J. 2020;56(6). Das N, Verstraete K, Stanojevic S, Topalovic M, Aerts J-M, Janssens W. Deep-learning algorithm helps to standardise ATS/ERS spirometric acceptability and usability criteria. Eur Respir J. 2020;56(6).
32.
go back to reference Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70–88.CrossRefPubMedPubMedCentral Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70–88.CrossRefPubMedPubMedCentral
33.
go back to reference Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.CrossRefPubMed Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.CrossRefPubMed
34.
go back to reference Veit T, Barnikel M, Crispin A, Kneidinger N, Ceelen F, Arnold P, et al. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study. Respir Res. 2020;21(1):270.CrossRefPubMedPubMedCentral Veit T, Barnikel M, Crispin A, Kneidinger N, Ceelen F, Arnold P, et al. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study. Respir Res. 2020;21(1):270.CrossRefPubMedPubMedCentral
35.
go back to reference Maher TM, Schiffman C, Kreuter M, Moor CC, Nathan SD, Axmann J, et al. A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease. Respir Res. 2022;23(1):307.CrossRefPubMedPubMedCentral Maher TM, Schiffman C, Kreuter M, Moor CC, Nathan SD, Axmann J, et al. A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease. Respir Res. 2022;23(1):307.CrossRefPubMedPubMedCentral
36.
go back to reference Confederation N. Patient empowerment: what is the role of technology in transforming care? 2023. Confederation N. Patient empowerment: what is the role of technology in transforming care? 2023.
Metadata
Title
Feasibility and acceptability of remotely monitoring spirometry and pulse oximetry as part of interstitial lung disease clinical care: a single arm observational study
Authors
Sarah Barth
Colin Edwards
Gauri Saini
Yussef Haider
Nicholas Paul Williams
Will Storrar
Gisli Jenkins
Iain Stewart
Melissa Wickremasinghe
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2024
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-024-02787-1

Other articles of this Issue 1/2024

Respiratory Research 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.